Showing results (181-190 of 202) with videos related to

Sort By:
Pageof 21
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 10, 2017
Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panelAlkis Togias, Susan F Cooper, Maria L Acebal, et al.
JAMA|February 23, 2019
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical TrialDavid M Fleischer, Matthew Greenhawt, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|June 24, 2015
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infantsDavid M Fleischer, Scott Sicherer, Matthew Greenhawt, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 1, 2015
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infantsDavid M Fleischer, Scott Sicherer, Matthew Greenhawt, et al.
Pediatric Dermatology|September 11, 2015
Consensus Communication on Early Peanut Introduction and Prevention of Peanut Allergy in High-Risk InfantsDavid M Fleischer, Scott Sicherer, Matthew Greenhawt, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Clinical and Translational Allergy|November 7, 2024
GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy managementTorsten Zuberbier, Antonella Muraro, Ulugbek Nurmatov, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2025
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEMatthew Greenhawt, Deborah Albright, Sara Anvari, et al.
Pageof 21